Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer

Inclusion Criteria

• •Histologically or cytologically confirmed small cell lung cancer (SCLC) (limited or extensive stage disease)
• •Progressive or recurrent disease after an initial response to first-line treatment with a platinum-based chemotherapy with or without concurrent definitive radiotherapy to the chest (chemotherapy must have been completed at least 90 days prior to documentation of relapse)
• •Measurable disease, defined as \>= 1 unidimensionally measurable lesion \>= 20 mm by conventional techniques OR \>= 10 mm by spiral CT scan
• •Lesions that are not considered measurable include the following:
• •* Bone lesions
• •* Leptomeningeal disease
• •* Ascites
• •* Pleural or pericardial effusion
• •* Abdominal masses that are not confirmed and followed by imaging techniques
• •* Cystic lesions
• •* Tumor lesions situated in a previously irradiated area, unless progression after radiotherapy is documented in these lesions
• •No known brain metastases (previously treated brain metastases allowed provided they are neurologically stable for \>= 4 weeks)
• •ECOG performance status 0-1
• •Platelet count \>= 100,000/mm\^3
• •Bilirubin =\< 1.5 times upper limit of normal (ULN)
• •Creatinine =\< 1.5 times ULN OR creatinine clearance \>= 60 mL/min
• •AST =\< 2.5 times ULN
• •Not pregnant or nursing
• •Negative pregnancy test
• •No significant cardiac disease, including any of the following:
• •* New York Heart Association class III-IV heart disease
• •* Myocardial infarction or ventricular tachyarrhythmia within the past 6 months
• •* Prolonged QTc \> 480 msec (Fridericia correction)
• •* Major conduction abnormality (unless a cardiac pacemaker is present)
• •No more than 1 prior chemotherapy regimen
• •No prior dasatinib or compounds of similar chemical composition or similar biologic therapeutic activity including, but not limited to, any inhibitors of SRC, BCR-ABL, c-KIT, EPHA2, or PDGFRB kinases
• •At least 2 weeks since prior definitive or palliative radiotherapy (prior radiotherapy allowed in the context of combined modality treatment with curative intent for limited stage disease; prophylactic cranial radiotherapy; or palliative radiotherapy initially or at relapse)
• •At least 2 weeks since prior surgery and recovered
• •At least 1 week since prior and no concurrent agents with proarrhythmic potential
• •At least 1 week since prior and no concurrent CYP3A4 inhibitors or inducers
• •At least 1 week since prior and no concurrent grapefruit concentrate
• •No concurrent palliative radiotherapy
• •No concurrent hormones or other chemotherapeutic agents, except steroids for adrenal failure, hormones for noncancer-related conditions (e.g., insulin for diabetes), or intermittent dexamethasone as an antiemetic
• •No concurrent combination antiretroviral therapy for HIV-positive patients
• •No other concurrent chemotherapeutic or investigational agents
• •Fertile patients must use effective contraception during and for \>= 6 weeks after completion of study therapy